Identification | Back Directory | [Name]
trans-4-[[[4-[1-(1,1-Dimethylethyl)-1H-pyrazol-4-yl]-2-pyridinyl][[4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]oct-1-yl]methyl]amino]carbonyl]cyclohexyl 3-hydroxy-1-azetidinecarboxylate | [CAS]
2414008-05-0 | [Synonyms]
FXR agonist 5 trans-4-[[[4-[1-(1,1-Dimethylethyl)-1H-pyrazol-4-yl]-2-pyridinyl][[4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]oct-1-yl]methyl]amino]carbonyl]cyclohexyl 3-hydroxy-1-azetidinecarboxylate | [Molecular Formula]
C40H53N5O5 | [MOL File]
2414008-05-0.mol | [Molecular Weight]
683.88 |
Chemical Properties | Back Directory | [Boiling point ]
810.6±65.0 °C(Predicted) | [density ]
1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
14.09±0.20(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
FXR agonist 5 (compound 1) is a FXR agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation[1]. | [References]
[1] Song Kenneth, et al. Farnesoid X receptor (FXR) agonists for the treatment of liver diseases or metabolic inflammation-mediated disorders. World Intellectual Property Organization, WO2021188688 A1. 2021-09-23. |
|
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
http://www.biorbyt.com |
|